GlassScriptPhysician profile
Nancy J Barrett
NPI 1457793853
$820.65
in general payments reported to CMS, 2019-2025
32 companies · $93.47 in 2025
The $93.47 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $170 · 2023: $349 · 2024: $209 · 2025: $93.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $87.00 | 2022 | |
| Recordati_rare_diseases_inc. | $56.35 | 2023-2025 | Sylvant, Enjaymo |
| Merck Sharp & Dohme LLC | $53.20 | 2022-2023 | Keytruda |
| Karyopharm Therapeutics INC. | $52.12 | 2023 | Xpovio |
| Beigene USA, INC. | $35.51 | 2023-2024 | Brukinsa |
| Janssen Biotech, INC. | $35.38 | 2022-2025 | Tecvayli, Darzalex |
| Abbvie INC. | $32.02 | 2024-2025 | |
| Genentech USA, INC. | $30.95 | 2023-2024 | Columvi, Lunsumio, Polivy |
| Jazz Pharmaceuticals INC. | $28.55 | 2023-2024 | |
| Sobi, INC | $25.97 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.80 | 2024 | Ninlaro |
| Novartis Pharmaceuticals Corporation | $24.28 | 2023 | |
| Alexion Pharmaceuticals, INC. | $21.62 | 2024 | Ultomiris |
| Iovance Biotherapeutics, INC. | $21.24 | 2025 | Amtagvi |
| Eisai INC. | $20.66 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $18.99 | 2023 | Injectafer |
| G1 Therapeutics, INC. | $18.72 | 2023 | Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $18.68 | 2022 | |
| Genzyme Corporation | $18.40 | 2023 | |
| Deciphera Pharmaceuticals INC. | $17.97 | 2024 | Qinlock |
| Novocure INC. | $17.83 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $16.25 | 2023 | |
| Servier Pharmaceuticals LLC | $16.20 | 2023 | |
| Adc Therapeutics America, INC. | $15.55 | 2022 | |
| Dendreon Pharmaceuticals LLC | $15.50 | 2023 | Provenge |
| Celltrion USA INC. | $15.25 | 2024 | Vegzelma |
| Array Biopharma INC | $14.63 | 2025 | Mektovi, Tukysa, Braftovi |
| Gilead Sciences, INC. | $13.84 | 2023 | |
| Incyte Corporation | $13.74 | 2023 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $13.34 | 2023 | Imbruvica |
| Acrotech Biopharma INC. | $13.33 | 2023 | Beleodaq |
| Astellas Pharma US INC | $12.78 | 2023 | Xospata |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.